# Modulation of tocotrienol’s bone effects by osteocytes: a perspective

**Authors:** Nurul Nabihah Zahanordin, Pei Yuen Ng, Kok-Yong Chin

PMC · DOI: 10.3389/fphar.2026.1773544 · Frontiers in Pharmacology · 2026-02-19

## TL;DR

This paper explores how tocotrienols, a form of vitamin E, may protect bones by influencing osteocytes, which are key cells in bone health.

## Contribution

The paper highlights the novel perspective that tocotrienols may act through osteocytes to improve bone quality.

## Key findings

- Tocotrienols reduce oxidative stress and modulate osteocyte-secreted factors like sclerostin and DMP1.
- TTs show protective effects on osteocytes in animal models of metabolic syndrome and ovariectomy.
- Current research is limited by model specificity and the need for advanced techniques to study TT mechanisms.

## Abstract

Osteocytes function as central regulators of skeletal health by acting as mechanosensors that control bone remodelling mediated by osteoblasts and osteoclasts. Disrupted osteocyte function, often driven by oxidative stress and linked to ageing and osteoporosis, contributes to pathological bone remodelling. Tocotrienols (TTs), a family of vitamin E, are intensively investigated for their bone-protective effects, with mechanisms that involve reducing intracellular reactive oxygen species, enhancing antioxidant defences, and modulating signalling pathways of bone remodelling. Preliminary studies suggest that TTs exert protective and anabolic effects by influencing osteocytes, including shielding them from oxidative damage. In vivo models using ovariectomised or metabolic syndrome rats demonstrated that TT supplementation modulated key osteocyte-secreted factors, including sclerostin, dentin matrix protein 1, Dickkopf-related protein 1, fibroblast growth factor 23, and receptor activator of nuclear factor κB ligand. However, the current evidence is limited by the use of models that may not fully represent degenerative osteoporosis, restricted dose-dependent studies, and the challenge of real-time in vivo monitoring. This perspective summarises the reported effects of TTs on osteocytes’ function and emphasises the critical need for future research to employ more representative animal models, advanced imaging techniques, and complex 3D co-culture or bone explant systems to accurately define the mechanism of action of TTs and their resulting functional outcomes on overall bone quality.

## Linked entities

- **Chemicals:** tocotrienols (PubChem CID 9929901)
- **Diseases:** osteoporosis (MONDO:0005298), metabolic syndrome (MONDO:0000816)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ctnnb1 (catenin beta 1) [NCBI Gene 84353] {aka Catnb}, Wnt2 (Wnt family member 2) [NCBI Gene 114487] {aka Wnt}, Runx2 (RUNX family transcription factor 2) [NCBI Gene 367218] {aka CBF-alpha-1, Cbfa1, OSF-2}, Hmgcr (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 25675] {aka 3H3M}, Dkk1 (dickkopf WNT signaling pathway inhibitor 1) [NCBI Gene 293897], Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619], Sp7 (Sp7 transcription factor) [NCBI Gene 300260] {aka Osx}, Smad4 (SMAD family member 4) [NCBI Gene 50554] {aka Madh4}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, Dmp1 (dentin matrix acidic phosphoprotein 1) [NCBI Gene 25312] {aka AG1, DENTMAT, DMP-1}, Tnfsf11 (TNF superfamily member 11) [NCBI Gene 117516] {aka ODF, OPGL, RANKL, TRANCE}, Fgf23 (fibroblast growth factor 23) [NCBI Gene 170583] {aka Fgf8b}, Casp1 (caspase 1) [NCBI Gene 25166] {aka Ice, Il1bc, p45}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Phex (phosphate regulating endopeptidase X-linked) [NCBI Gene 25512] {aka PEX}, Sost (sclerostin) [NCBI Gene 80722], Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 287362] {aka Cias1}
- **Diseases:** fragility fractures (MESH:D005600), resorption (MESH:D014091), skeletal deterioration (OMIM:616592), obesity (MESH:D009765), bone (MESH:D001847), Osteoporosis (MESH:D010024), osteoporotic (MESH:D058866), PN (MESH:C565820), fracture (MESH:D050723), Mitochondrial dysfunction (MESH:D028361), stunted growth (MESH:D006130), inflammation (MESH:D007249), Metabolic syndrome (MESH:D024821)
- **Chemicals:** chromanol (MESH:C029141), annatto (MESH:C054041), ROS (MESH:D017382), palm oil (MESH:D000073878), PGE2 (MESH:D015232), GSH (MESH:D005978), GSSG (MESH:D019803), carbon (MESH:D002244), TPs (MESH:D024505), alpha-TT (MESH:C082032), carbohydrate (MESH:D002241), tert-butyl hydroperoxide (MESH:D020122), romosozumab (MESH:C557282), vitamin E (MESH:D014810), delta-TT (MESH:C082097), homocysteine (MESH:D006710), denosumab (MESH:D000069448), phosphate (MESH:D010710), TT (MESH:D024508), HFHC (-), mevalonate (MESH:D008798)
- **Species:** Bixa orellana (achiote, species) [taxon 66672], Oryza sativa (Asian cultivated rice, species) [taxon 4530], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MLO-Y4 — Mus musculus (Mouse), Transformed cell line (CVCL_M098)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960167/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12960167/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960167/full.md

---
Source: https://tomesphere.com/paper/PMC12960167